Autor: |
Chalirmporn Atasilp, Rinradee Lenavat, Natchaya Vanwong, Phichai Chansriwong, Ekaphop Sirachainan, Thanyanan Reungwetwattana, Pimonpan Jinda, Somthawin Aiempradit, Suwannee Sirilerttrakul, Monpat Chamnanphon, Apichaya Puangpetch, Nipaporn Sankuntaw, Patompong Satapornpong, Chonlaphat Sukasem |
Jazyk: |
angličtina |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
Frontiers in Oncology, Vol 12 (2022) |
Druh dokumentu: |
article |
ISSN: |
2234-943X |
DOI: |
10.3389/fonc.2022.916650 |
Popis: |
BackgroundThe two common methylenetetrahydrofolate reductase (MTHFR) polymorphisms 677G>A and 1298A>C may have been affecting 5-FU toxicity in cancer patients for decades. Drug efficacy has also been shown by previous studies to be affected. In this study, we investigated the effects of these polymorphisms on 5-FU hematological toxicity and treatment efficacy, to provide enhanced pharmacological treatment for cancer patients.MethodsThis is a retrospective study involving 52 Thai colorectal cancer patients who were treated with 5-FU based therapy, using TaqMAN real-time PCR to genotype the MTHFR polymorphisms (677G>A and 1298A>C). The toxicity and response rate were assessed using standardized measures.ResultsNeutropenia was significantly more likely to be experienced (P=0.049, OR=7.286, 95% CI=0.697-76.181) by patients with the MTHFR 677G>A polymorphism, in the same way as leukopenia (P =0.036, OR=3.333, 95%CI=2.183-5.090) and thrombocytopenia (PC polymorphism had no statistical association with hematological toxicity in 5-FU treatment. The response rate to 5-FU was not significantly affected by these two polymorphisms.ConclusionThe MTHFR polymorphism 677G>A is a significant risk factor for developing leukopenia, neutropenia and thrombocytopenia as toxic effects of 5-FU therapy in cancer patients. Therefore, patients receiving 5-FU-based therapy should be aware of their polymorphisms as one risk factor for experiencing severe toxicity. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|